Scott J. Diede

Merck & Co., Inc.

Kenilworth, NJ

United States

SCHOLARLY PAPERS

1

DOWNLOADS

23

CITATIONS

0

Scholarly Papers (1)

1.

Epacadostat Plus Pembrolizumab versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma: Results of the Phase 3, Randomised, Double-Blind Echo-301/Keynote-252 Study

Number of pages: 39 Posted: 05 Feb 2019
The University of Sydney - Melanoma Institute Australia, University Hospital Zurich, Angeles Clinic and Research Institute, University of Chicago - Medical Center, Universidad del Desarrollo - Facultad de Medicina Clínica Alemana, University of Lyon 1, Hospital Clinic of Barcelona, The University of Sydney - Melanoma Institute Australia, Aix-Marseille University, Seoul National University - Seoul National Hospital, N.N. Blokhin Russian Cancer Research Center, Université Paris XI Sud - Gustave Roussy Cancer Campus, Royal Marsden NHS Foundation Trust, Merck & Co., Inc., Incyte Corporation, Incyte Corporation, Merck & Co., Inc. and University of Pennsylvania, Perelman School of Medicine, Abramson Family Cancer Research Institute
Downloads 23 (498,233)

Abstract:

Loading...

melanoma, indoleamine 2,3-dioxygenase, epacadostat, pembrolizumab, immunotherapy